Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)

Abstract The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved u...

Full description

Bibliographic Details
Main Authors: Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Christian Blank, Richard D. Carvajal, Sandra Demaria, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Roger S. Lo, Georgina V. Long, Jason J. Luke, Iman Osman, Michael A. Postow, Ryan J. Sullivan, Janis M. Taube, Giorgio Trinchieri, Hassane M. Zarour, Corrado Caracò, Magdalena Thurin
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Journal of Translational Medicine
Subjects:
Melanoma
Immunotherapy
Anti-PD-1
Anti-CTLA-4
Target therapy
Biomarkers
Online Access:http://link.springer.com/article/10.1186/s12967-020-02482-x

Internet

http://link.springer.com/article/10.1186/s12967-020-02482-x

Similar Items